Home > News > Insert Therapeutics Files IND Application
February 9th, 2006
Insert Therapeutics Files IND Application
Abstract:
Arrowhead Research Corporation (Nasdaq:ARWR) announced today that its majority-owned subsidiary Insert Therapeutics, Inc. has submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) for IT-101, its first anti-cancer drug candidate. Cyclosert is a proprietary drug delivery technology based on a nano-engineered class of linear cyclodextrin polymers.
Source:
businesswire
Related News Press |
Nanomedicine
New micromaterial releases nanoparticles that selectively destroy cancer cells April 5th, 2024
Good as gold - improving infectious disease testing with gold nanoparticles April 5th, 2024
Researchers develop artificial building blocks of life March 8th, 2024
Announcements
NRL charters Navy’s quantum inertial navigation path to reduce drift April 5th, 2024
Discovery points path to flash-like memory for storing qubits: Rice find could hasten development of nonvolatile quantum memory April 5th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||